RSS
SUPN icon

Rosenblum Silverman Sutton’s Supernus Pharmaceuticals SUPN Stock Holding History

Rosenblum Silverman Sutton’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,200
Closed -$288K – 68
2017
Q3 		$288K Buy
+7,200
New +$312K 0.11% 64

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Rosenblum Silverman Sutton's SUPN Position: Q4 2017 in Review

Rosenblum Silverman Sutton sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 7,200 shares — an estimated $288K sold.

Rosenblum Silverman Sutton first reported a position in SUPN in Q3 2017 and held it in 1 quarter. The position peaked at $288K in Q3 2017. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • Rosenblum Silverman Sutton reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Rosenblum Silverman Sutton sold 7,200 Supernus Pharmaceuticals shares in Q4 2017, an estimated $288K.
  • Rosenblum Silverman Sutton first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Rosenblum Silverman Sutton's Supernus Pharmaceuticals position peaked at $288K in Q3 2017.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Rosenblum Silverman Sutton's 13F filing for Q4 2017, filed 1 Feb 2018.